RXi Q2 Loss Rises 18 Percent on Increased Operating Costs | GenomeWeb

RXi Pharmaceuticals last week reported its second-quarter financial results, posting a more than 18 percent rise in its net loss on a nearly identical increase in operating costs.

For the three-month period ended June 30, RXi reported no revenues and a jump in its net loss to $5.1 million, or $0.37 per share, from $4.3 million, or $0.34 per share, a year earlier.

Research and development spending climbed to $3 million from $2.8 million, while general and administrative costs edged up to $2 million from $1.6 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.